Dr. Bruce Leuchter is a co-founder of Neurvati Neurosciences and GRIN Therapeutics and was named President, CEO and board member of Neurvati when the company was established in September 2021. His extensive experience in neuroscience spans clinical research and patient care as well as investment banking, equity research and medical technology. He has served as a senior advisor on matters related to clinical research, corporate strategy, M&A transactions, and financings for many leading life sciences companies.

A physician by training and neuropsychiatrist by specialty, Dr. Leuchter brings a depth of understanding of the unmet need and patient experience in the diagnosis and treatment of neuropsychiatric disorders to Neurvati. He completed his residency training in neurology and psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a diplomate of the American Board of Psychiatry and Neurology. He also served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College, where maintains a voluntary faculty appointment in the Department of Psychiatry.

He has held leadership roles at leading financial services companies including biotechnology equity research analyst at Goldman Sachs, healthcare investment banking at Credit Suisse, and mergers and acquisitions at PJT Partners. He is also a co-founder and founding neuropsychiatrist of Click Therapeutics, a digital therapeutics company that specializes in the treatment of neurological and psychiatric disorders.

Dr. Leuchter is a member of the Scientific Advisory Committee for the Daedalus Fund for Innovation at Weill Cornell Medical College and a member of the Life Science Institute Leadership Council at the University of Michigan. He earned his BA at the University of Michigan and his MD at Wayne State University School of Medicine.